Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. (CHRS) announced the granting of stock options to 16 new employees as of June 16, 2022.

(Moderate)

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Coherus BioSciences, Inc. (CHRS) announced the granting of stock options to 16 new employees as of June 16, 2022. A total of 409,000 shares were made available, with a per-share exercise price of $5.86, the closing price on the grant date. The options include 200,000 shares for a Chief level executive and 45,000 shares for a Vice President, while 14 non-officer employees received a combined total of 164,000 shares. This initiative is part of the 2016 Employment Commencement Incentive Plan aimed at attracting new talent.

Positive

Granting stock options to attract and incentivize new talent.
Total of 409,000 shares granted, indicating company growth.

Negative

None.

Argus Session date unavailable

+10.13% session move Open Argus

Details

News Market Reaction – CHRS

The recorded move for CHRS in the trading session of this news was +10.13%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/22/2022 - 04:30 PM

REDWOOD CITY, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 16, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 409,000 shares of the common stock of the Company to 16 newly hired employees with a per share exercise price of $5.86, the closing trading price on the grant date. One newly-hired Chief level executive was granted options to purchase 200,000 shares and one Vice President was granted options to purchase 45,000 shares. 14 non-officer employees were granted options to purchase an aggregate of 164,000 shares.

The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Coherus BioSciences grant on June 16, 2022?

On June 16, 2022, Coherus BioSciences granted options to purchase 409,000 shares of common stock to 16 new employees.

What was the exercise price of the stock options granted by Coherus?

The exercise price for the stock options was set at $5.86, the closing trading price on the grant date.

Who received the largest stock option grants at Coherus BioSciences?

The largest stock option grant was 200,000 shares to a newly hired Chief level executive.

What is the purpose of the 2016 Employment Commencement Incentive Plan at Coherus?

The plan aims to induce new employees to join Coherus BioSciences by offering equity grants.

Keep reading

Trending in the feed

PCRX

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies Open the live feed